Australia's Immutep rises on positive US FDA feedback for lung cancer drug

Immutep

16/05/2023 03:51

** Shares of biotech co Immutep  IMM.AX  rise as much as
4.4% to A$0.235, set for best session since May 4, if gains hold
    ** Co receives positive feedback from the U.S. Food and Drug
Administration (FDA) for late-stage clinical development of
eftilagimod alpha (efti) for treatment of non-small cell lung
cancer
    ** Says FDA is supportive of a registration trial to
evaluate efti in combination with an anti-PD-1 therapy 
    ** Stock down ~18.2% this year, as of last close 
    


 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))